Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients

NCT01657214 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
70
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi